Basilixumab Biosimilar – Anti-IL-2 receptor mAb – Research Grade

Description of Basilixumab Biosimilar - Anti-IL-2 receptor mAb - Research Grade

Introduction

Basiliximab biosimilar is a monoclonal antibody (mAb) that targets the interleukin-2 (IL-2) receptor, making it a promising therapeutic option for various immune-mediated diseases. In this article, we will explore the structure, activity, and applications of this biosimilar in detail.

Structure

Basiliximab biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 145 kDa. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody has a variable region that specifically binds to the alpha chain of the IL-2 receptor, and a constant region that mediates effector functions.

Activity

The IL-2 receptor is found on the surface of activated T cells and plays a crucial role in their proliferation and survival. Basiliximab biosimilar binds to the alpha chain of this receptor, preventing IL-2 from binding and activating the receptor. This results in the inhibition of T cell activation and proliferation, which is beneficial in the treatment of various immune-mediated diseases.

Applications

Basiliximab biosimilar has been approved for use in the treatment of two main conditions: acute rejection in renal transplantation and prophylaxis of acute graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (HSCT).

Renal Transplantation

Acute rejection is a major complication after renal transplantation, occurring in approximately 10-25% of cases. Basiliximab biosimilar has been shown to significantly reduce the incidence of acute rejection when used in combination with other immunosuppressive agents. This is due to its ability to target and inhibit activated T cells that are responsible for the rejection of the transplanted organ.

Allogeneic HSCT

GVHD is a serious complication that can occur after allogeneic HSCT, where the donor’s immune cells attack the recipient’s tissues. Basiliximab biosimilar has been approved for use as prophylaxis against acute GVHD in combination with other immunosuppressive agents. By inhibiting the activation and proliferation of T cells, it helps to prevent the development of this life-threatening condition.

Other Potential Applications

Apart from its approved indications, there is ongoing research on the potential use of basiliximab biosimilar in other immune-mediated diseases. Some of the conditions being studied include autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Additionally, there is also interest in using this biosimilar in the treatment of certain types of cancer, as IL-2 is known to play a role in tumor growth and progression.

Conclusion

In summary, basiliximab biosimilar is a monoclonal antibody that targets the IL-2 receptor and has been approved for use in the prevention of acute rejection in renal transplantation and acute GVHD in allogeneic HSCT. Its ability to inhibit T cell activation and proliferation makes it a promising therapeutic option for various immune-mediated diseases. Ongoing research is exploring its potential use in other conditions, making it an exciting area of study in the field of immunotherapy.